Phase 3 results lol - They're hoping for the AMRN effect?
NEW YORK, Nov. 29, 2010 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) will host a conference call tomorrow, Tuesday, November 30th, at 8:30am ET to review the top-line results from the Phase 3 short-term efficacy study component of its Phase 3 registration program of Zerenex™ (ferric citrate), the Company's ferric iron-based phosphate binder for the treatment of elevated serum phosphorous levels, or hyperphosphatemia, in patients with end-stage renal disease on dialysis. Keryx will announce the top-line results tomorrow morning, prior to the call.
